Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Development of a robust classifier for quality control of reverse-phase protein arrays.

Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR.

Bioinformatics. 2015 Mar 15;31(6):912-8. doi: 10.1093/bioinformatics/btu736. Epub 2014 Nov 6.

2.

LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer.

Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG.

Cancer Metab. 2013 Aug 14;1(1):18. doi: 10.1186/2049-3002-1-18.

3.

Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.

Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J.

PLoS One. 2013 Aug 1;8(8):e70608. doi: 10.1371/journal.pone.0070608. Print 2013.

4.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20.

5.

Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.

Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV.

J Thorac Oncol. 2010 Dec;5(12):1894-904. doi: 10.1097/JTO.0b013e3181f2a266.

6.

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB.

J Oncol. 2010;2010:568938. doi: 10.1155/2010/568938. Epub 2009 Nov 19.

7.

Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.

Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H.

Cancer Res. 2009 Mar 15;69(6):2461-70. doi: 10.1158/0008-5472.CAN-08-3236. Epub 2009 Mar 10.

8.

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM.

Cancer Res. 2009 Jan 15;69(2):565-72. doi: 10.1158/0008-5472.CAN-08-3389.

9.

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G.

Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.

10.

Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.

Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC, Logsdon CD.

Proteomics. 2008 Aug;8(15):3051-60. doi: 10.1002/pmic.200700951.

11.

Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.

Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S.

FASEB J. 2007 Sep;21(11):2918-30. Epub 2007 Apr 20.

PMID:
17449721
12.

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR.

Mol Cancer Ther. 2007 Apr;6(4):1414-24.

13.

A module of negative feedback regulators defines growth factor signaling.

Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y.

Nat Genet. 2007 Apr;39(4):503-12. Epub 2007 Feb 25.

PMID:
17322878
15.

KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2.

Zang XP, Siwak DR, Nguyen TX, Tari AM, Pento JT.

Clin Exp Metastasis. 2004;21(5):437-43.

PMID:
15672868
16.

The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.

Mendoza-Gamboa E, Siwak DR, Tari AM.

Oncol Rep. 2004 Oct;12(4):903-8.

PMID:
15375520
17.

Liposomal antisense oligonucleotides for cancer therapy.

Siwak DR, Tari AM, Lopez-Berestein G.

Methods Enzymol. 2004;387:241-53. No abstract available.

PMID:
15172168
18.

HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells.

Siwak DR, Mendoza-Gamboa E, Tari AM.

Int J Oncol. 2003 Dec;23(6):1739-45.

PMID:
14612949
19.

Src activation regulates anoikis in human colon tumor cell lines.

Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE.

Oncogene. 2002 Nov 7;21(51):7797-807.

21.

"Mitotic drive" of expanded CTG repeats in myotonic dystrophy type 1 (DM1).

Khajavi M, Tari AM, Patel NB, Tsuji K, Siwak DR, Meistrich ML, Terry NH, Ashizawa T.

Hum Mol Genet. 2001 Apr 1;10(8):855-63.

PMID:
11285251

Supplemental Content

Support Center